We identified the demographics of 385 health care workers (HCWs) to identify those whose chance of developing a protective response to a standard primary hepatitis B immunization series was so high that the need for testing for antibodies to hepatitis B surface antigen (anti-HBs) would be obviated following immunization. In addition, using sensitivity analysis, we analyzed the economic consequences of not determining anti-HBs titers for any individual after primary immunization and of using the Centers for Disease Control and Prevention (CDC)-recommended post -hepatitis B exposure prophylaxis for high-risk HCWs. Nonsmoking women õ50 years old with a weight-height index of õ42 had a 98.2 { 0.9% chance of developing a protective anti-HBs titer. Male nonsmokers õ50 years old with a weight-height index of õ29 had a 94.7 { 1.8% chance of a protective response. Economic analysis revealed that use of the CDC guidelines for post -hepatitis B exposure prophylaxis in male HCWs whose anti-HBs status is unknown is always more cost-effective than determining anti-HBs titers following primary immunization for those at high risk. In female HCWs, posthepatitis B exposure prophylaxis is more cost-effective until hepatitis B exposure rates are Ç50%. It is possible to predict who will have a high probability of developing a protective response to hepatitis B vaccine; for these people, determining postimmunization anti-HBs titers is unnecessary and not cost-effective.
Hepatitis B viral infection and its sequelae are a major health myces cerevisiae. While these recombinant vaccines are effective, recent data suggest that 10-mg doses of Recombivax HB problem in the United States, involving Ç1 million infectious carriers and 200,000 -300,000 new acute infections annually.
have a somewhat higher failure rate in inducing protection than do 20-mg doses of Engerix-B [2, 3]. Each year, Ç4,000 -5,000 persons die of hepatitis B -related chronic liver disease and hepatocellular carcinoma. The most effective way to prevent hepatitis B infection is immunization See editorial response by Henderson on pages 572 -4. with hepatitis B vaccine [1] .
Two types of hepatitis B vaccines have been commercially The recommended dosing of hepatitis B vaccine is a series available in the United States. The first (no longer used) hepatiof three intramuscular doses given at 0, 1, and 6 months. who are unprotected fall into two categories: hyporesponders (anti-HBs, 2.1 -9.9 mIU/mL) and nonresponders (anti-HBs, õ2.1 mIU/mL) [5] . Data on homosexual men suggest that when nonresponders are revaccinated with one additional dose, 567 CID 1998; 26 (March) Postvaccination Hepatitis B Testing
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vancing age, increased body-mass index, male sex, smoking [2, 4, 8] , and impaired immunity [9 -11] . Antibody response Medical records of 1,036 employees immunized between to hepatitis B vaccine has also been associated with the major 1989 and 1994 were retrospectively reviewed. Collected data histocompatibility complex [11 -15] Fisher's exact tests were employed for statistical testing of titers and giving the postexposure prophylaxis to persons who dichotomous variables. Subsequently, the identified significant are known to have had HBsAg exposure.
predictors of response were subjected to multivariate analysis The purpose of this study was to identify host factors that using stepwise logistic regression. A P value of £.05 was predict the development of a protective vaccine response or considered statistically significant. nonresponse, in order to define those for whom it is necessary Posterior probabilities were calculated from the significant to assess anti-HBs titers post-immunization. In addition, we host variables and their joint effects. The posterior probabilities analyzed the economic impact of not determining anti-HBs were used to define a profile of individuals with the highest titers for any high-risk health care worker post-immunization likelihood of response and nonresponse. In order to obtain and simply administering the recommended postexposure proclinically useful data from posterior probability analysis, conphylactic regimen following exposure to hepatitis B.
tinuous variables (e.g., WHI and age) were categorized as dichotomous variables by examining a graphic analysis of response to determine an appropriate cutpoint.
Methods
The Institutional Review Board of Bassett Healthcare (CooEconomic Analysis perstown, NY) approved this study by expedited review. Because no subject identifiers were obtained during data collection Economic analysis of the consequences of nonresponse was performed as follows. The primary purpose of immunization (i.e., name, medical record number, etc.), informed consent was not required. Subjects were identified through a computerof high-risk health care workers is to prevent nosocomial transmission of hepatitis B following percutaneous exposure to a generated list from Employee Health Services at our institution. Health care workers who received three doses of Engerix-B patient who is HBsAg-positive. Table one illustrates the total cost (with use of the CDC algorithm) of evaluating and treating (20 mg at 0, 1, and 6 { 1 months) and had an anti-HBs titer determined within 1 -6 months after the third injection were an immunized health care worker with an unknown anti-HBs status who has been exposed to a patient infected with hepatitis included in the study. All subjects received hepatitis B vaccine intramuscularly in the deltoid muscle by means of a 23-gauge, was assessed for the health care worker (and assumed to be õ10 mIU/mL), and that a single dose of hepatitis B vaccine { 1 months) or did not have an anti-HBs titer determined and hepatitis B immune globulin (HBIG) were administered within 1 -6 months of last injection. to the health care worker.
The subjects' demographics and response rates are shown The cost of any laboratory analyses includes reagent, labor, in table 2. Ninety-nine percent of the subjects were white. and maintenance contract costs at our institution. In addition, Seventy-three (19%) of the subjects were cigarette smokers. we used the average wholesale price (AWP) to estimate vaccine Among our population of health care workers, 48% were in and immunoglobulin costs. The AWP is a standardized national OSHA exposure-risk category I, 9% in category II, and 43% source for pricing; however, it grossly overstates our instituin category III. Of the 385 subjects, 355 were classified as tion's cost for hepatitis B vaccine (actually $17.58/dose) and responders and 30 as nonresponders. HBIG (actually $173/dose). Use of the AWP biases the model in favor of determining anti-HBs titers post-immunization.
Analysis of Response
The univariate analyses identified four host factors that are Sensitivity Analysis significant predictors of response: age, sex, WHI, and smoking The scenario used for analyzing the economic impact of not status (table 3) . When age was analyzed as a dichotomous measuring anti-HBs following hepatitis B vaccination of highrisk health care workers is as follows. From the data of Neu- The availability of hepatitis B vaccine has also contributed tile) were found to be the cutpoints. Stepwise logistic regression to a reduction of disease in persons at risk. Currently the CDC revealed that sex, age, and WHI (as continuous variables), as recommends a three-dose series followed by assessment of the well as smoking status, remain significant independent preanti-HBs titer to document response in high-risk health care dictors of response (table 4) in a multivariate model. Overall, workers. Determining this titer increases the cost of a vaccine nonsmokers were 7.7 times more likely to respond to vaccine.
course by Ç$9.27. If it is possible to identify those persons Using posterior probability analysis, we calculated probabilwith a high rate of response, the follow-up determination of ity of response for our population (table 5). We found that the anti-HBs titer and its costs could be avoided. male nonsmokers who were õ50 years of age and whose WHI Our results show that female nonsmokers õ50 years of age was õ29 had a 94.7 { 1.8% probability of developing a protecwith a WHI of õ42 have a 98.2% probability of response. tive antibody response. Female nonsmokers õ50 years of age Consequently, assessment of anti-HBs titers to document prowhose WHI was õ42 had a 98.2 { 0.9% probability of protectection in this population are probably not needed. Male nontion. In contrast, male smokers õ50 years of age with a WHI smokers õ50 years of age with a WHI of õ29 have a 94.7% of §29 had a 66.3 { 9.5% probability of response, while probability of response. Checking anti-HBs titers may be unfemale smokers õ50 years of age with a WHI of §42 had a necessary in this group also. 68.1 { 7.1% probability of protection. Additional group reOur data suggest that the main risk factor in nonresponse to sponse rates are given in table 5.
hepatitis B vaccine is smoking status. Age of §50 years, male Of the 30 nonresponders, 24 subjects had additional doses sex, and increasing body size are also predictive but less so. administered in an attempt to induce a protective antibody
Smoking has been shown to result in increased cytotoxic/supresponse: 8 received one, 13 received two, and 3 received three pressor and decreased inducer/helper T-cell numbers as well additional doses. Of these 24 subjects, 16 developed protective as lowered immunoglobulin titers [26] , and these may be the levels of anti-HBs. mechanisms of action for nonresponse to hepatitis B vaccination. Thus, one might make the argument to check anti-HBs Economic Analysis
On the basis of the economic data in table 1, the cost of postexposure prophylaxis against hepatitis B for a previously Table 5 . Probability of response to hepatitis B vaccine, based on vaccinated health care worker (exposed to an HBsAg-positive dichotomous subject characteristics. patient) whose anti-HBs status is unknown (and when determined at the time of exposure is shown to be õ10 mIU/mL) Response 
Smoking
No. of probability is $279.66. titers only in smokers, males §50 years of age, males with a Our data suggest that certain groups of adults have high response rates to hepatitis B vaccine. We recommend that high-WHI of §29, and females with a WHI of §42. However, while this may be effective in reducing costs of immunization, risk health care workers who fall into these high-response categories do not need to have anti-HBs titers determined at comthis two-tiered recommendation may result in confusion about who needs postvaccination anti-HBs titers checked.
pletion of a three-dose series. A conservative approach would be to measure anti-HBs titers in all smokers, in males who are In order to make a recommendation generally applicable to the population of high-risk health care workers, we also con- §50 years of age and whose WHI is §29, and in females whose WHI is §42. ducted an economic analysis of the cost of determining antiHBs titers following a three-dose series of hepatitis B vaccinaHowever, to avoid the confusion of a two-tiered approach for checking anti-HBs titers, our economic analysis suggests tions vs. not determining them for any immunized health care worker but following the CDC recommendations for postexpothat it is cost-effective to conduct postexposure testing of the patient and exposed worker and treat the worker with HBIG sure prophylaxis for hepatitis B. As noted in table 6, the cost of determining postimmunization anti-HBs titers for 1,000 perand one additional dose of hepatitis B vaccine (if the patient is positive for hepatitis B antigen) rather than to assess antisons ($9,270) is substantially more than the cost of postexposure prophylaxis until the frequency rates of exposure approxiHBs titers routinely for high-risk health care workers who complete a primary immunization series of hepatitis B vaccinations mate 50% (for women). Because of lower exposure rates, measuring postimmunization anti-HBs titers in male health care on schedule. This cost-effective strategy would eliminate any confusion from a two-tiered approach in recommending the workers is never cost-effective.
Since hepatitis B exposure among high-risk female health checking of anti-HBs titers in only those health care workers who are at risk of nonresponse to hepatitis B vaccine, and it care workers is considerably less than 50% [22] and since a high proportion of vaccinated women are responders, routine should reduce the overall cost of immunization. assessment of postimmunization titers is not cost-effective. It vaccine is unknown.
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